VEGFA Involves in the Use of Fluvastatin and Zoledronate Against Breast Cancer
- 155 Downloads
Our study aimed to identify key genes involved in the use of fluvastatin and zoledronate against breast cancer, as well as to investigate the roles of vascular endothelial growth factor A (VEGFA) in the malignant behaviors of breast cancer cells. The expression data GSE33552 was downloaded from Gene Expression Omnibus database, including mocked-, fluvastatin- and zoledronate-treated MDA-MB-231 cells. Differentially expressed genes (DEGs) were identified in fluvastatin- and zoledronate-treated cells using limma package, respectively. Pathway enrichment analysis and protein-protein interaction (PPI) network analysis were then performed. Then we used shRNA specifically targeting VEGFA (shVEGFA) to knock down the expression of VEGFA in MDA-MB-231 cells. Cell viability assay, scratch wound healing assay, Transwell invasion assay and flow cytometry were performed to explore the effects of VEGFA knockdown on the malignant behaviors of breast cancer cells. VEGFA was up-regulated in both fluvastatin- and zoledronate-treated breast cancer cells. Moreover, VEGFA was a hub node in PPI network. In addition, VEGFA was successfully knocked down in MDA-MB-231 cells by shVEGFA. Suppression of VEGFA promoted the migration and invasion of breast cancer MDA-MB-231 cells. Suppression of VEGFA inhibited the apoptosis of MDA-MB-231 cells. Our results indicate that up-regulation of VEGFA may prevent the progression of breast cancer after fluvastatin and zoledronate treatment via inducing cell apoptosis and inhibiting migration and invasion. VEGFA may serve as a potential prognostic indicator for clinical outcome in the management of breast cancer.
KeywordsFluvastatin Zoledronate Breast cancer Genes
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Stebbing J, Slater S, Slevin M (2006) Breast cancer (metastatic). Clin Evid 15:2331–2359Google Scholar
- 5.Kanugula AK, Gollavilli PN, Vasamsetti SB, Karnewar S, Gopoju R, Ummanni R, Kotamraju S (2014) Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms. FEBS J 281(16):3719–3738CrossRefPubMedGoogle Scholar
- 7.Dedes P, Gialeli C, Tsonis A, Kanakis I, Theocharis A, Kletsas D, Tzanakakis G, Karamanos N (2012) Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta 1820(12):1926–1939CrossRefPubMedGoogle Scholar
- 12.Smyth GK (2005) Limma: linear models for microarray data. In: Bioinformatics and computational biology solutions using R and Bioconductor. Springer, pp 397–420Google Scholar
- 17.Cory G (2011) Scratch-wound assay. Cell Migration. Springer, In, pp 25–30Google Scholar
- 20.Yin YP, Wei WH, Wang HC, Zhu BY, Yu YH, Chen XS, Peeling RW, Cohen MS (2009) Performance of serological tests for syphilis in sexually transmitted diseases clinics in Guangxi Autonomous Region, China: implications for syphilis surveillance and control. Sex Health 6(1):5–9CrossRefPubMedGoogle Scholar
- 26.Rydén L, Stendahl M, Jonsson H, Emdin S, Bengtsson NO, Landberg G (2005) Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res Treat 89(2):135–143CrossRefPubMedGoogle Scholar
- 30.Ma X, Shen D, Li H, Zhang Y, Lv X, Huang Q, Gao Y, Li X, Gu L, Xiu S (2015) MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau–inactivated clear cell renal cell carcinoma. In: Urologic Oncology: Seminars and Original Investigations. Elsevier, pp 169. e161–169. e111Google Scholar